Roche Reports Results of Tecentriq (atezolizumab) + Avastin (bevacizumab) in P-III IMbrave150 for Unresectable Hepatocellular Carcinoma at ESMO Congress 2019

Shots:

• The P-III IMbrave150 study involve assessing of Tecentriq (1200mg, IV) + Avastin (IV, 15 mg/kg) vs Sorafenib (PO, 400mg, bid) in 501 patients in a ratio 2:1 with unresectable HCC prior not treated with systemic therapies
• The P-III IMbrave 150 study results: 42% reduction in risk of death, 41% reduction in risk of disease worsening; mOS (not reached vs 13.2mos.); mPFS (6.8 mos. vs 4.3mos.) measured as per IRF RECIST v1.1.; median follow-up 8.6 months; AEs (57% vs 55%), presented at ESMO Congress 2019
• Tecentriq is mAb targeting PD-L1 which is expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1receptors. The dual regimen combat multiple cancer indications as Avastin enhances Tecentriq ability to restore anti-cancer immunity, by inhibiting VEGF related immunosuppression

Click here to­ read full press release/ article | Ref: Roche | Image: Watsons